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Letters to the EditorBiological or relational screening for liver disease?To the Editor:
As a member of the ‘‘discordantist’’ family [1] I agree with Dr. Poy-
nard’s proposal of non invasive methods as a ﬁrst line investigation
forassessmentof liverﬁbrosis [2].However, fromapublichealthand
ﬁnancial point of view, a ‘‘sequentialist’’ attitude in case of liver dis-
ease could probably be a more preferable recommendation.
Another aspect of Dr. Poynard’s proposal to screen general
population for liver ﬁbrosis by using biomarkers is very
questionable:
It seems more satisfactory to screen, at ﬁrst line, the etiological
factors, than for their liver consequences. As pointed in Dr. Poy-
nard’s study [3], in a general population, almost 9 out of 10 cases
of conﬁrmed liver ﬁbrosis can be attributed to metabolic causes
(alcohol and more importantly non alcoholic fatty liver disease).
Instead of considering new biological tests for screening, it is more
important to teach and promote screening, by general practitioners
and other ﬁrst line health professionals, for premature mortality
risk factors: overweight, obesity, and sedentarity related metabolic
syndrome, at risk or excessive alcohol consumption, and tobacco,
without forgetting risk factors for viral hepatitis B and C. Such a
screening should be more efﬁcient from a global individual and
public health point of view: it is possible to have metabolic
syndrome or alcohol excessive intake without conﬁrmed liver
ﬁbrosis but (more frequently!) with other somatic complications
(especially cardiovascular and/or tumoral diseases).
The use of biomarkers without screening for overweight,
obesity, sedentarity, at risk or excessive alcohol consumption,
tobacco, or viral hepatitis B and C risk factors will be nonsense:
if evaluation for conﬁrmed liver ﬁbrosis by biomarkers was posi-
tive, screening for these factors would be a secondary necessity.
However, in case of conﬁrmed liver ﬁbrosis excluded by biomark-
ers, it will be necessary to screen for the same risk factors. So
what is the interest to test the general population by biomarkers,
instead of only screening for suspected liver ﬁbrosis in patients
with risk factors?
At this state of the discussion, a frequent comment is: ‘‘you
could be right but after the recognition of risk factors, what do
you propose?’’ suggesting a negative answer. But the same
answer is also possible (except in case of cirrhosis) after bio-
markers screening for metabolic liver disease! And in fact this
comment is wrong: a lot of Evidence Based Medicine (EBM)
behavioral and cognitive data has been published, showingJournal of Hepatology 2signiﬁcant and durable results in weight loss and physical
activity in patients with overweight, obesity, and diabetes.
These results have been conﬁrmed recently for patients with
non alcoholic steatohepatitis [4]. It is not the place to develop
more extensively this aspect, but just one example: a very
recent paper showed a strong association between practitioners
saying clearly to the patient the diagnosis of obesity, its impor-
tance for health, and the obtention of signiﬁcant and durable
weight loss [5]. We have to look carefully not only for EBM
data about biological and morphological tests, drug, or surgical
treatment but also for behavioral and cognitive EBM data. Sci-
entiﬁc rigour should not accept fragmentation and only par-
tially taking into account available data.
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To the Editor:
We read with interest the paper of Kurosaki and colleagues [1]
and applaud their use of data mining to develop a decision tree
to predict HCV treatment outcomes. We agree with them that
prediction of treatment outcome is very important in the process
of physician and patient making a decision to commence treat-011 vol. 55 j 1162–1167
